黑料网

Predictive Oncology has canceled its Special Meeting of Stockholders originally set for December 1, 2020, due to insufficient quorum as only 47% of shares were voted. Despite this, nearly 88% of those who voted supported the proposal to reincorporate from Delaware to Nevada, primarily to avoid high franchise taxes. The Board will pursue stockholder approval for this reincorporation in the future. Predictive Oncology leverages AI in personalized medicine, operating through segments like Helomics and Skyline Medical.

Predictive Oncology (NASDAQ: POAI) announced the reconvening of its virtual Special Meeting of Stockholders to December 30, 2020, at 3 p.m. CST. The company urges shareholders to vote 'FOR' the proposal to reincorporate in Nevada, which would eliminate an annual Delaware franchise tax of approximately $170,000, saving about $158,000 annually. The board believes Nevada's laws provide better protections for the company and its officers. The reincorporation requires majority approval from outstanding shares, as previous votes did not meet the threshold.

Predictive Oncology (NASDAQ: POAI) announced that its Special Meeting of Stockholders, originally scheduled for December 1, 2020, was adjourned due to lack of quorum. The meeting will reconvene on December 30, 2020, at 3 p.m. CST, via live audio webcast. Stockholders of record, dated as of October 28, 2020, are encouraged to vote by proxy to ensure their votes are counted. The company operates through three segments with a focus on applying artificial intelligence in drug discovery and personalized medicine.

Predictive Oncology (POAI) reported its Q3 2020 financial results, maintaining revenues at $0.5 million, similar to the previous year. The company achieved a gross margin of 64%, up from 60%, attributed to reduced manufacturing costs. However, operating loss rose to $5.6 million, influenced by a $3.0 million non-cash goodwill impairment. The net loss increased to $6.9 million, or $(0.46) per share, compared to $(1.31) per share in 2019. Business highlights included signing a contract with a pharmaceutical company and licensing 71 unique ovarian cancer cell lines, bringing the total to 96.

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz discussed the company's recent milestones and future goals in an interview with NetworkNewsWire. Key subsidiaries highlighted include TumorGenesis, which has developed a novel lab media to replace animal testing for tumors, and Soluble Biotech, which has expanded its research capabilities. Schwartz also emphasized Helomics' extensive tumor data, which positions it for competitive success in the market. The full interview provides further insights into these developments and the company's strategic direction.

Predictive Oncology (NASDAQ: POAI) released a letter from CEO Carl Schwartz addressing shareholders amid a declining stock price. Despite this downturn, he assures investors of positive progress, highlighting stable cash burn and increasing revenue trends. The company鈥檚 divisions, including Skyline Medical and Helomics, are experiencing operational advancements, with new product launches and successful collaborations. Predictive Oncology is poised for growth, with solid cash reserves and strategic partnerships on the horizon, aiming for revenue generation by year-end.

TumorGenesis, a division of Predictive Oncology (NASDAQ: POAI), has acquired a license for 71 unique ovarian cancer cell lines, increasing its total to 96. This was done in collaboration with Ximbio, enhancing research capabilities in ovarian cancer. The new media developed for these cells retains over 95% of DNA and RNA, providing a robust tool for researchers. Richard Gabriel, President of TumorGenesis, emphasized that this advancement addresses the challenges presented by standard media mixes and aims to improve reproducibility in preclinical research, potentially saving the industry billions in research costs.

Predictive Oncology (NASDAQ: POAI) announced its participation in the LD Micro's LD 500 Virtual Investor Conference, scheduled for September 2, 2020, at 3:40 PM ET. The event will provide an opportunity for company management to present and discuss its advancements in artificial intelligence applied to personalized medicine and drug discovery. A live webcast will be available to the public and archived for 90 days. For more details, visit .

Predictive Oncology (NASDAQ: POAI) announced the sale of 8 STREAMWAY systems to a Virginia university hospital for a new surgical center, adding to the 2 systems already in use. This transaction is anticipated to yield approximately 4,000 procedures annually. In total, the company has sold 13 STREAMWAY systems in Q3 2020. The STREAMWAY System automates medical fluid disposal, showcasing POAI's advancements in personalized medicine and AI application in drug discovery.